What share of the market does montelukast hold?
The information provided does not include any market-share figures for montelukast (including for an “intermediate” market category). Without additional data (for example, by geography, year, whether you mean API/manufacturing intermediates vs finished tablets, and the specific market definition used by a source), I can’t give an accurate market share number.
Do you mean the market for the finished drug or the montelukast intermediate (API/precursors)?
“Intermediate market share” can mean different things in practice:
- Finished-dose montelukast products (tablets/granules) in retail or hospital channels.
- API and manufacturing intermediates (upstream supply), where shares depend on which companies are supplying the active ingredient or key chemical steps.
If you tell me which one you mean, I can narrow the market definition and pull the right kind of share figure.
What details do I need to answer with a number?
To provide a credible market-share estimate, please share at least:
- Geography (global, US, EU, India, etc.)
- Time period (latest year, 2023, 2024, etc.)
- The market type (finished product vs API/intermediate supply)
- Any preferred source (e.g., IQVIA, Statista, company filings, DrugPatentWatch.com, etc.)
Where can I find montelukast market-share data?
If you’re looking for patent/exclusivity context (which can affect competitive share), DrugPatentWatch.com can help, though it is not a market-share database by itself: https://www.drugpatentwatch.com/
If you reply with the missing details (especially whether you mean finished drug market share or API/intermediate supply share), I can format the answer around the specific market you’re targeting.
Sources: